Medicalgorithmics S.A. — Regulatory Filings 2023

Sep 26, 2023

Subject:Information on Adjustments in Consolidated Comparable Data for 2022 ofthe Medicalgorithmics S.A. Capital Group

CurrentReport No.: 26/2023

Date ofPreparation: September 26, 2023

Legal Basis:Art. 17 sec. 1 of MAR Regulation - confidential information.

The ManagementBoard of Medicalgorithmics S.A. ("The Company" or "Issuer") informsabout the subject and nature of corrections in consolidated comparabledata for the year 2022, which the Company made while working on thesemi-annual consolidated financial statement of the MedicalgorithmicsS.A. Group (Group) for the first half of 2023. These corrections arenon-cash and relate to accounting records and calculations of thenon-cash accounting result concerning the disposal and deconsolidationof Medi-Lynx Cardiac Monitoring, LLC ("Medi-Lynx") and transactions andcorrections related to this transaction. These corrections do not affectthe Group's cash flows, neither in the current period nor in the future.In particular, as part of the corrections, the opening balance (OB) ofconsolidated equity as of January 1, 2023, increased by PLN 14.6million, consisting of a reduction in net loss for 2022 from minus PLN30.4 million to minus PLN 11.9 million (by PLN 18.5 million). The fullimpact of the corrections is presented in the attached statements oftotal income and financial position as of and for the 12 months endedDecember 31, 2022, as published, with the detailing of aggregatecorrections and post-correction.

The stand-alonereport data for 2022 do not require any corrections, including regardingthe disposal of Medi-Lynx. In accordance with IAS 8 par. 41, the effectsof these corrections have been included in the comparable data and inthe opening balances as of January 1, 2023, therefore, the Company doesnot correct the published and approved consolidated financial statementsfor 2022. The review of opening balances, which led to theidentification of the described corrections, was made during thepreparation of the Group's interim report, and its results are subjectto review by the new company auditor, UHY ECA Audyt Sp. z o.o., engagedafter the expiration of a two-year contract with Grant Thornton PolskaP.S.A.

The Companypoints out that the consolidated semi-annual financial statements of theGroup are subject to verification by an independent auditor, UHY ECA, aspart of the process of reviewing the semi-annual statements,consequently, there may be possibility of changing the indicated amountsor the way they are presented. In the case of significant changes, theCompany will inform about it with separate current reports.

Detailed legalbasis: Article 17(1) of Regulation (EU) No 596/2014 of the EuropeanParliament and of the Council of 16 April 2014 on market abuse (marketabuse regulation) and repealing Directive 2003/6/EC of the EuropeanParliament and of the Council and Commission Directives 2003/124/EC,2003/125/EC and 2004/72/EC and §15 section 5 of the Regulation of theMinister of Finance of 29 March 2018 on current and periodic informationpublished by issuers of securities the value and the conditions forrecognizing as equivalent information required by the laws of anon-Member State.

Attachments tothe report:

1.Transformation of comparable data with summary of corrections (inPolish).